Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? (Q36817040)

16 August 2017

1 reference

title

Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees? (English)

1 reference

16 August 2017

0 references

5

1 reference

16 August 2017

Paula I Moreira

4

0 references

Xiongwei Zhu

series ordinal

2

object named as

Xiongwei Zhu

1 reference

16 August 2017

6

Mark A Smith

1 reference

16 August 2017

3

Hyoung-gon Lee

1 reference

16 August 2017

Rudy J Castellani

1

1 reference

16 August 2017

1 May 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

5

1 reference

16 August 2017

473-485

1 reference

Alzheimer Disease in the US Population

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Predicting the failure of amyloid-beta vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Neuropathology of Alzheimer disease: pathognomonic but not pathogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Copernicus revisited: amyloid beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid beta: the alternate hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Cellular mechanisms of beta-amyloid production and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Alzheimer's disease is a synaptic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The role of A beta 42 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Protein oxidation in aging brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Rapid induction of Alzheimer A beta amyloid formation by zinc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Interaction between the zinc (II) and the heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Determination of cadmium and zinc in Alzheimer's brain tissue using inductively coupled plasma mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

In-vivo measurement of activated microglia in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Complement activation by beta-amyloid in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Cell cycle events in neurons. Proliferation or death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Phosphoprotein phosphatase activities in Alzheimer disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Alzheimer Neurofibrillary Degeneration: Therapeutic Targets and High-Throughput Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Staging of Alzheimer's disease-related neurofibrillary changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The glial cell glutamate uptake carrier countertransports pH-changing anions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The time course of glutamate in the synaptic cleft

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The cholinergic system in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Presynaptic cholinergic dysfunction in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Acetylcholinesterase inhibitors: novel activities of old molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Cholinesterase inhibitors: new roles and therapeutic alternatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Growth-factor gene therapy for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Regulation of cell survival by secreted proneurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

The many faces of p75NTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Dual role for p75(NTR) signaling in survival and cell death: can intracellular mediators provide an explanation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

p75 neurotrophin receptor signaling: mechanisms for neurotrophic modulation of cell stress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Increased p27, an essential component of cell cycle control, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Therapeutic opportunities in Alzheimer disease: one for all or all for one?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Arson. Tracking the culprit in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Feasibility of treating mild cognitive impairment withcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Genuine Monovalent Ligands of TrkA Nerve Growth Factor Receptors Reveal a Novel Pharmacological Mechanism of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.473

21 January 2018

Identifiers

DOI

10.1586/14737175.7.5.473

1 reference

release_rftfoisnafeljd7eoyf3if5icm

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rftfoisnafeljd7eoyf3if5icm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

17492899

1 reference

PubMed ID

17492899